Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 32405062.
- Also identified by DOI 10.1038/s41591-020-0856-x and PMC identifier 8127102.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Serum interleukin-8 (IL-8) levels and tumor neutrophil infiltration are associated with worse prognosis in advanced cancers. Here, using a large-scale retrospective analysis, we show that elevated baseline serum IL-8 levels are associated with poor outcome in patients (n = 1,344) with advanced cancers treated with nivolumab and/or ipilimumab, everolimus or docetaxel in phase 3 clinical trials, revealing the importance of assessing serum IL-8 levels in identifying unfavorable tumor immunobiology and as an independent biomarker in patients receiving immune-checkpoint inhibitors.
Medical subject headings
- Antineoplastic Agents, Immunological
- Biomarkers, Pharmacological
- Interleukin-8
- Neoplasms
- Neutrophils
- Protein Kinase Inhibitors